MBRX Insider Trading
Insider Ownership Percentage: 1.90%
Insider Buying (Last 12 Months): $349,999.65
Insider Selling (Last 12 Months): $0.00
Moleculin Biotech Share Price & Price History
Current Price: $0.55
Price Change: ▲ Price Increase of +0.0161 (3.01%)
As of 07/11/2025 05:00 PM ET
Moleculin Biotech Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
6/23/2025 | Jonathan P Foster | CFO | Buy | 270,270 | $0.37 | $99,999.90 | 287,587 | |
6/23/2025 | Walter V Klemp | CEO | Buy | 675,675 | $0.37 | $249,999.75 | 743,607 | |
12/26/2023 | Jonathan P Foster | CFO | Buy | 1,932 | $10.35 | $19,996.20 | 5,370 | |
12/26/2023 | Robert E George | Director | Buy | 966 | $10.35 | $9,998.10 | 977 | |
12/26/2023 | Walter V Klemp | CEO | Buy | 12,560 | $10.35 | $129,996.00 | 45,392 | |
11/25/2022 | Walter V Klemp | CEO | Buy | 3,000 | $19.20 | $57,600.00 | 27,326 | |
11/21/2022 | Walter V Klemp | CEO | Buy | 1,500 | $17.25 | $25,875.00 | 24,326 | |
11/16/2022 | Walter V Klemp | CEO | Buy | 5,680 | $14.55 | $82,644.00 | 21,176 | |
Moleculin Biotech Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
5/15/2025 | Armistice Capital LLC | 1,250,000 | $1.22M | 0.0% | +293.6% | 8.929% |  |
8/15/2024 | Armistice Capital LLC | 156,000 | $0.55M | 0.0% | +5.1% | 6.747% |  |
2/13/2024 | Armistice Capital LLC | 3,207,417 | $2.75M | 0.0% | N/A | 9.600% |  |
1/17/2024 | Atticus Wealth Management LLC | 50,001 | $43K | 0.0% | N/A | 0.168% |  |
5/15/2023 | Sio Capital Management LLC | 1,010,956 | $0.97M | 0.5% | -2.5% | 3.407% |  |
7/25/2022 | Walker Asset Management LLC | 20,708 | $32K | 0.0% | N/A | 0.072% |  |
4/20/2022 | Sigma Planning Corp | 57,500 | $0.10M | 0.0% | +33.7% | 0.201% |  |
2/2/2022 | Sigma Planning Corp | 43,000 | $80K | 0.0% | N/A | 0.150% |  |
11/9/2021 | BlackRock Inc. | 270,402 | $0.81M | 0.0% | -2.5% | 0.947% |  |
9/17/2021 | Virtu Financial LLC | 25,302 | $93K | 0.0% | N/A | 0.089% |  |
8/16/2021 | Occudo Quantitative Strategies LP | 29,188 | $0.11M | 0.0% | +31.7% | 0.102% |  |
8/16/2021 | State Street Corp | 59,900 | $0.22M | 0.0% | N/A | 0.210% |  |
8/13/2021 | Geode Capital Management LLC | 237,586 | $0.87M | 0.0% | +35.9% | 0.835% |  |
8/13/2021 | Vanguard Group Inc. | 1,047,529 | $3.84M | 0.0% | +123.6% | 3.683% |  |
8/12/2021 | XTX Topco Ltd | 32,997 | $0.12M | 0.0% | N/A | 0.116% |  |
8/5/2021 | GSA Capital Partners LLP | 31,120 | $0.11M | 0.0% | N/A | 0.109% |  |
5/21/2021 | Citadel Advisors LLC | 13,843 | $56K | 0.0% | N/A | 0.049% |  |
5/19/2021 | Squarepoint Ops LLC | 28,904 | $0.12M | 0.0% | +134.2% | 0.102% |  |
5/18/2021 | Cubist Systematic Strategies LLC | 26,624 | $0.11M | 0.0% | N/A | 0.094% |  |
5/18/2021 | Citadel Advisors LLC | 13,843 | $56K | 0.0% | N/A | 0.049% |  |
5/12/2021 | Northern Trust Corp | 50,731 | $0.21M | 0.0% | -43.1% | 0.178% |  |
5/12/2021 | Geode Capital Management LLC | 174,822 | $0.71M | 0.0% | -40.6% | 0.615% |  |
5/7/2021 | BlackRock Inc. | 239,326 | $0.98M | 0.0% | +449.7% | 0.841% |  |
Data available starting January 2016
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Read More on Moleculin Biotech
Volume
2,850,825 shs
Average Volume
2,483,576 shs
Market Capitalization
$7.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.38
Who are the company insiders with the largest holdings of Moleculin Biotech?